Fourth quarter net revenues increased 8% year-over-year to 174350000, primarily driven by higher active patients on therapy, while net loss improved to 24499000 compared to 65922000 in the prior year period.
Total net revenues grew 8% year-over-year to 174350000.
Gross margin declined to 76% from 79% in the prior year.
Net loss narrowed to 24499000 from 65922000 year-over-year.
Total active patients increased to 4620 compared to 4126 last year.
For full year 2026, Novocure expects total net revenues between 675000000 and 705000000 and adjusted EBITDA between -20000000 and 0.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance